News

Global Health Challenges: Addressing the antimicrobial resistance crisis

There is a challenge that has captured the attention of most experts in the field of global health: antimicrobial resistance. This growing trend towards antibiotics and drugs that are ineffective against current pathologies poses a serious obstacle to the treatment…

Challenging antibiotic resistance: Fungi against pneumonia, gonorrhoea and intestinal diseases

In the modern era of medicine, advances in antibiotics have saved countless lives, effectively treating diseases caused by pathogens such as Streptococcus pneumoniae, Neisseria gonorrhoeae and Campylobacter Jejuni. However, these micro-organisms, which are responsible for serious diseases such as pneumonia,…

HIFAS Biologics and “One Health”: An alliance to defend public health

In the 21st century, the accelerating pace of globalisation, climate change and urbanisation has brought public health concerns into the spotlight. The connection between human and environmental health has become more evident than ever, demonstrating that any disruption to an…

Hifas Biologics and the CSIC join forces in an innovative collaboration to develop antimicrobial peptides to fight multidrug-resistant infections

Hifas Biologics, a leader in the early development of antimicrobials from fungi, is proud to announce an exciting collaboration with the Spanish National Research Council (CSIC) specifically with the IPNA (Institute of Natural Products and Agrobiology). This strategic partnership, which…

Hifas Biologics joins the prestigious biotechnology startup acceleration program “SiloAceleraBio” coordinated by SILO in collaboration with ASEBIO.

Hifas Biologics, a leading company in the early development of antimicrobials from fungal origin, has been selected to participate in the renowned biotechnology company acceleration program “SiloAceleraBio”. This inclusion in SiloAceleraBio marks a significant milestone for Hifas Biologics, consolidating its…

The growing concern about antibiotic resistance opens the door to a new model of financing and disruptive strategies for obtaining them

Advances in studies of the One Health approach have fostered greater awareness that antibiotic resistance is a major problem. Nevertheless, the low profitability of the antibiotic development process has meant that SMEs are currently the only ones carrying out this…

La OMS publica el Programa de Investigación Prioritaria sobre la Resistencia a los Antimicrobianos (RAM)

Este programa de investigación primaria engloba a la Organización de las Naciones Unidas para la Agricultura y la Alimentación (FAO), el Programa de las Naciones Unidas para el Medio Ambiente (PNUMA), la División de RAM de la Organización Mundial de…

40 priority research topics will form the basis of the policy-directive-technical guide on antimicrobial resistance in 2030

Antimicrobial resistance in the human health sector is the priority focus of the global research agenda, which is centered on 40 research themes concerning WHO’s priority bacterial and fungal pathogens of critical importance for antimicrobial resistance, as well as drug-resistant…